Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models

Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating peroxisome proliferator-activated receptors (PPAR). These studies evaluate the efficacy and safety profile of Saroglitazar in preclinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Mukul R, Giri, Suresh R, Trivedi, Chitrang, Bhoi, Bibhuti, Rath, Akshyaya, Vanage, Geeta, Vyas, Purvi, Ranvir, Ramchandra, Patel, Pankaj R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492752/
https://www.ncbi.nlm.nih.gov/pubmed/26171220
http://dx.doi.org/10.1002/prp2.136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492752/
https://www.ncbi.nlm.nih.gov/pubmed/26171220
http://dx.doi.org/10.1002/prp2.136

Ejemplares similares